What is Wedbush’s Estimate for LRMR FY2029 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at Wedbush cut their FY2029 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on Thursday, November 6th. Wedbush analyst L. Chico now expects that the company will earn $0.75 per share for the year, down from their previous forecast of $0.83. Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share.

Larimar Therapeutics (NASDAQ:LRMR) last announced its earnings results on Wednesday, November 5th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.22).

Several other equities analysts have also recently commented on LRMR. Oppenheimer dropped their target price on shares of Larimar Therapeutics from $26.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, October 2nd. Robert W. Baird decreased their price target on Larimar Therapeutics from $10.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities cut their price objective on Larimar Therapeutics from $22.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Friday, August 15th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $3.46 on Friday. Larimar Therapeutics has a 52-week low of $1.61 and a 52-week high of $9.50. The company has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $3.37. The company has a market capitalization of $286.42 million, a price-to-earnings ratio of -1.79 and a beta of 1.10.

Institutional Investors Weigh In On Larimar Therapeutics

Hedge funds have recently modified their holdings of the stock. B.O.S.S. Retirement Advisors LLC purchased a new position in Larimar Therapeutics in the third quarter valued at approximately $41,000. Savant Capital LLC purchased a new stake in Larimar Therapeutics in the second quarter worth $39,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Larimar Therapeutics in the second quarter valued at $44,000. Walleye Capital LLC purchased a new position in shares of Larimar Therapeutics during the 1st quarter valued at $37,000. Finally, Next Level Private LLC purchased a new position in shares of Larimar Therapeutics during the 2nd quarter valued at $58,000. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.